ANON
MCID: ANR007
MIFTS: 64

Anorexia Nervosa (ANON)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Anorexia Nervosa

MalaCards integrated aliases for Anorexia Nervosa:

Name: Anorexia Nervosa 57 12 75 74 55 44 15 17 72 33
Anorexia Nervosa, Susceptibility to, 1 57 13 40
Anorexia Nervosa 1 57 29
Anon 57 74
Anorexia Nervosa, Susceptibility to 57
an 57

Classifications:



External Ids:

Disease Ontology 12 DOID:8689
OMIM 57 606788
ICD9CM 35 307.1
MeSH 44 D000856
NCIt 50 C34387
SNOMED-CT 68 56882008
ICD10 33 F50.0 F50.00
MedGen 42 C1853221
UMLS 72 C0003125

Summaries for Anorexia Nervosa

OMIM : 57 Eating disorders are characterized by severe disturbances in eating behavior that typically have onset during late adolescence and early adulthood. Three major types are recognized: anorexia nervosa (AN), bulimia nervosa (BN; 607499), and eating disorder not otherwise specified (EDNOS). AN is characterized by obsessive fear of weight gain, severely restricted eating, and low body weight. In women, AN has the highest mortality among the psychiatric disorders (Sullivan, 1995). AN is divided into 2 clinical subtypes, restricting anorexia nervosa (RAN) and binge-eating/purging anorexia nervosa (BPAN). BN can occur at any body weight and is characterized by binge-eating and compensatory weight-loss behaviors. Family studies have indicated an increased prevalence of eating disorders in relatives of probands with AN (Lilenfeld et al., 1998), and twin studies (Holland et al., 1984; Wade et al., 2000) have estimated concordance rates for monozygotic twins with AN to be 52 to 56%, whereas concordance rates for dizygotic twins with AN have been estimated to be 5 to 11% (Grice et al., 2002). (606788)

MalaCards based summary : Anorexia Nervosa, also known as anorexia nervosa, susceptibility to, 1, is related to acanthosis nigricans and traumatic brain injury, and has symptoms including decrease in appetite An important gene associated with Anorexia Nervosa is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Fluoxetine and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and testes, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology : 12 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

UniProtKB/Swiss-Prot : 74 Anorexia nervosa: An eating disorder characterized by the lack or loss of appetite, excess fear of becoming overweight, body image disturbance, significant weight loss, refusal to maintain minimal normal weight, and amenorrhea.

Wikipedia : 75 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder, characterized by low... more...

Related Diseases for Anorexia Nervosa

Diseases related to Anorexia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 13097)
# Related Disease Score Top Affiliating Genes
1 acanthosis nigricans 33.5 PRL LEP IGF1 ADIPOQ
2 traumatic brain injury 32.6 IGF1 GH1 BDNF
3 eating disorder 32.4 SLC6A4 PYY POMC NPY LEPR LEP
4 amenorrhea 32.3 PRL POMC LEP CRH
5 apnea, obstructive sleep 32.1 LEP HTR2A ADIPOQ
6 mccune-albright syndrome 32.1 PRL IGF1 GH1
7 personality disorder 32.1 SLC6A4 PRL HTR2A BDNF
8 pseudohypoparathyroidism, type ia 32.0 PRL IGF1 GH1
9 allergic encephalomyelitis 32.0 POMC CRH
10 acquired generalized lipodystrophy 32.0 RETN LEP ADIPOQ
11 laron syndrome 32.0 IGF1 GHR GH1
12 fibrous dysplasia 31.9 PRL IGF1 GH1
13 empty sella syndrome 31.9 PRL POMC IGF1 GH1
14 bulimia nervosa 31.9 SLC6A4 PYY NPY LEP HTR2A GHRL
15 depression 31.8 SLC6A4 HTR2A CRH BDNF
16 intermittent explosive disorder 31.8 SLC6A4 PRL NPY
17 nutritional deficiency disease 31.8 LEP IGF1 GHRL
18 sleep apnea 31.8 LEPR LEP IGF1 HTR2A GHRL ADIPOQ
19 gestational diabetes 31.8 RETN LEP ADIPOQ
20 coronary artery aneurysm 31.8 RETN LEP ADIPOQ
21 3-hydroxyacyl-coa dehydrogenase deficiency 31.8 RETN LEP GHRL ADIPOQ
22 obsessive-compulsive disorder 31.8 SLC6A4 PRL HTR2A CRH BDNF
23 atypical depressive disorder 31.7 SLC6A4 HTR2A CRH
24 anxiety 31.7 SLC6A4 NPY HTR2A CRH BDNF
25 borderline personality disorder 31.7 SLC6A4 HTR2A BDNF
26 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 31.7 POMC LEP
27 social phobia 31.7 SLC6A4 PRL CCK
28 chiasmal syndrome 31.7 PRL POMC
29 substance abuse 31.7 SLC6A4 PRL NPY BDNF
30 pancreas disease 31.7 POMC LEP IGF1 CCK
31 pituitary adenoma 1, multiple types 31.6 PRL IGF1 GH1
32 retrograde amnesia 31.6 SLC6A4 POMC
33 constipation 31.6 SLC6A4 PYY NPY CCK
34 central precocious puberty 31.6 IGF1 GH1
35 hyperthyroidism 31.5 PRL LEP GHRL GH1
36 gigantism 31.5 PRL GHRH GH1
37 mental depression 31.4 SLC6A4 POMC HTR2A CRH BDNF
38 anovulation 31.4 PRL LEP IGF1
39 hyperinsulinism 31.4 LEP IGF1 GHRL GH1
40 psychotic disorder 31.3 SLC6A4 PRL HTR2A BDNF
41 isolated growth hormone deficiency, type ii 31.3 IGF1 GHRH GHR GH1
42 paranoid schizophrenia 31.3 SLC6A4 HTR2A BDNF
43 hypothyroidism 31.2 RETN PRL POMC LEP IGF1 GH1
44 generalized anxiety disorder 31.2 SLC6A4 HTR2A BDNF
45 schizoaffective disorder 31.2 SLC6A4 PRL HTR2A BDNF
46 mood disorder 31.2 SLC6A4 POMC NPY HTR2A CRH BDNF
47 gastroesophageal reflux 31.2 PYY GHRL CCK
48 endogenous depression 31.1 SLC6A4 NPY HTR2A CRH BDNF
49 alcohol dependence 31.1 SLC6A4 POMC NPY HTR2A GHRL CCK
50 hypothyroidism, congenital, nongoitrous, 4 31.1 PRL POMC IGF1 GH1 CRH

Comorbidity relations with Anorexia Nervosa via Phenotypic Disease Network (PDN):


Acute Cystitis Major Depressive Disorder
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Anorexia Nervosa:



Diseases related to Anorexia Nervosa

Symptoms & Phenotypes for Anorexia Nervosa

Clinical features from OMIM:

606788

UMLS symptoms related to Anorexia Nervosa:


decrease in appetite

GenomeRNAi Phenotypes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGRP BDNF GHR GHRL IGF1 POMC

MGI Mouse Phenotypes related to Anorexia Nervosa:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ADIPOQ AGRP BDNF CCK CRH GHR
2 behavior/neurological MP:0005386 10.36 ADIPOQ AGRP BDNF CRH GHR GHRL
3 endocrine/exocrine gland MP:0005379 10.34 ADIPOQ BDNF CCK CRH GHR GHRH
4 adipose tissue MP:0005375 10.3 ADIPOQ AGRP CRH GHR GHRL IGF1
5 growth/size/body region MP:0005378 10.29 ADIPOQ AGRP BDNF CRH GHR GHRH
6 liver/biliary system MP:0005370 10.14 ADIPOQ AGRP CRH GHR GHRH LEP
7 integument MP:0010771 10.13 ADIPOQ BDNF CRH GHR IGF1 LEP
8 nervous system MP:0003631 10.13 ADIPOQ AGRP BDNF CCK CRH GHR
9 muscle MP:0005369 9.91 ADIPOQ GHR HTR2A IGF1 LEP LEPR
10 normal MP:0002873 9.81 AGRP BDNF CRH GHRL IGF1 LEPR
11 neoplasm MP:0002006 9.8 ADIPOQ IGF1 LEP LEPR POMC PRL
12 renal/urinary system MP:0005367 9.61 ADIPOQ CCK CRH GHR IGF1 LEP
13 skeleton MP:0005390 9.28 ADIPOQ CRH GHR HTR2A IGF1 LEP

Drugs & Therapeutics for Anorexia Nervosa

Drugs for Anorexia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
2
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5
Cycloserine Approved Phase 4 68-41-7 6234 401
6
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
7
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
8
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
9
Memantine Approved, Investigational Phase 4 19982-08-2 4054
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
12 Raclopride Investigational Phase 4 84225-95-6
13 Serotonin Uptake Inhibitors Phase 4
14 Antidepressive Agents Phase 4
15 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
16 Antidepressive Agents, Second-Generation Phase 4
17 Cytochrome P-450 Enzyme Inhibitors Phase 4
18 Neurotransmitter Uptake Inhibitors Phase 4
19 Serotonin Agents Phase 4
20 Psychotropic Drugs Phase 4
21 Antiemetics Phase 4
22 Tranquilizing Agents Phase 4
23 Central Nervous System Depressants Phase 4
24 Gastrointestinal Agents Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Antipsychotic Agents Phase 4
27 Autonomic Agents Phase 4
28 Analgesics Phase 4
29 Serotonin Receptor Agonists Phase 4
30 Dopamine Agents Phase 4
31 Serotonin 5-HT2 Receptor Antagonists Phase 4
32 Serotonin Antagonists Phase 4
33 Serotonin 5-HT1 Receptor Agonists Phase 4
34 Dopamine Antagonists Phase 4
35 Dopamine agonists Phase 4
36 Dopamine D2 Receptor Antagonists Phase 4
37 Renal Agents Phase 4
38 Anti-Bacterial Agents Phase 4
39 Antitubercular Agents Phase 4
40 Antibiotics, Antitubercular Phase 4
41 Anti-Infective Agents, Urinary Phase 4
42 Anti-Infective Agents Phase 4
43 Antimetabolites Phase 4
44 Quetiapine Fumarate Phase 4 111974-72-2
45 Sympathomimetics Phase 4
46 Adrenergic Agents Phase 4
47 Dopamine Uptake Inhibitors Phase 4
48 Antiparkinson Agents Phase 4
49 Excitatory Amino Acid Antagonists Phase 4
50 Excitatory Amino Acids Phase 4

Interventional clinical trials:

(show top 50) (show all 294)
# Name Status NCT ID Phase Drugs
1 Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
2 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
3 Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
4 Fluoxetine After Weight Restoration in Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
5 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
6 An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity Completed NCT00330655 Phase 4 memantine
7 Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial: The EFFORT Trial Completed NCT02517476 Phase 4
8 NMDA Antagonists in Bipolar Depression Completed NCT01833897 Phase 4 Standard of Care;Ketamine;D-cycloserine
9 Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
10 Efficacy of Aripiprazole in the Treatment of Anorexia Nervosa in Teenagers: a Pilot, Randomised, Double Blind, Placebo-controlled Clinical Trial Unknown status NCT01082848 Phase 3 aripiprazole;placebo
11 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
12 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
13 IGF-1 and Bone Loss in Women Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
14 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
15 Cannabinoid CB1 Receptor Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
16 Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
17 Effects of Anorexia Nervosa on Peak Bone Mass Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
18 The Role of Lactobacillus Reuteri in Nutritional Recovery and Treatment of Constipation in Children and Adolescents With Anorexia Nervosa - Randomised, Double Blind, Placebo Controlled Study Completed NCT02004288 Phase 2, Phase 3
19 Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
20 Effect of Adrenal and Gonadal Hormones on Bone Marrow and Appendicular BMD Completed NCT01343771 Phase 3 DHEA (Prasterone) + ERT (Aviane)
21 Combination Pharmacotherapy With Chantix & Bupropion for Smoking Cessation (ChanBan) Completed NCT00587769 Phase 3 Bupropion SR & Varenicline
22 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients Completed NCT00221442 Phase 3 Zonegran;sugar pill
23 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa. Therapeutic Trial of Growth Hormone Active, not recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
24 Effects of Anorexia Nervosa on Peak Bone Mass Active, not recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
25 Assessment of the Effect of Gluten Free Toothpaste on the Ulcerative Events in Children With Celiac Disease (Before and After Pilot Study) Not yet recruiting NCT03771443 Phase 3 experimental gluten free toothpaste
26 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Terminated NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
27 Evaluation of the Efficacy and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Children and Adolescents: An Open-label Trial Terminated NCT01184443 Phase 3 Olanzapine
28 A 10-week Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Omega-3 Fatty Acids Oral Capsules Compared With Placebo in the Treatment of Anorexia Nervosa Unknown status NCT01761942 Phase 2
29 Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa: A Randomized Control Trial Unknown status NCT01611220 Phase 2
30 The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer Unknown status NCT03245658 Phase 2 THC and CBD Mixture
31 A Phase 2, Investigator-Initiated, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2 RM-131;Placebo
32 The Role of PTH in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2 Placebo;Teriparatide
33 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
34 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
35 Effects of Recombinant Human Insulin Like Growth Factor-1 (rhIGF-1) on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
36 Treatment for Adolescent Anorexia Nervosa Completed NCT00183586 Phase 2
37 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Completed NCT02475265 Phase 2 estradiol 0.045 mg/levonorgestrel 0.015mg
38 The Effect of Ortho Tri-Cyclen on Bone Mineral Density in Pediatric Subjects With Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
39 Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
40 Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study Completed NCT00260962 Phase 2 Olanzapine
41 Therapeutic Effects of Alpha-neurofeedback in the Treatment of Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
42 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
43 Atypical Antipsychotic Medication in Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
44 Treatment of Anxiety and Anorexia Nervosa in Adolescents Completed NCT01933243 Phase 2 Fish oil;Placebo pill
45 Addressing Fear of Food in Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
46 Family Therapy for Adolescent Bulimia Nervosa: A Controlled Comparison Completed NCT00518843 Phase 2
47 CRAFT: Helping Parents Initiate and Support Their Adolescent's Treatment Completed NCT01344382 Phase 1, Phase 2
48 The Role of Estrogen in the Neurobiology of Eating Disorders: A Study of Cognitive Flexibility and Reward in Eating Disorders Recruiting NCT03740204 Phase 2 17-β estradiol transdermal patches with cyclic progesterone;Placebo patch and pill
49 Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa Not yet recruiting NCT03875378 Phase 2 Transdermal estrogen;Placebos
50 A Clinical Trial Into the Efficacy of rTMS Treatment for Treating Anorexia Nervosa and Bulimia Nervosa Not yet recruiting NCT04061304 Phase 2

Search NIH Clinical Center for Anorexia Nervosa

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amitriptyline
Citalopram
Cyproheptadine
Desipramine
Fluoxetine

Cochrane evidence based reviews: anorexia nervosa

Genetic Tests for Anorexia Nervosa

Genetic tests related to Anorexia Nervosa:

# Genetic test Affiliating Genes
1 Anorexia Nervosa 1 29 HTR2A

Anatomical Context for Anorexia Nervosa

MalaCards organs/tissues related to Anorexia Nervosa:

41
Bone, Brain, Testes, Pituitary, Heart, Bone Marrow, Liver

Publications for Anorexia Nervosa

Articles related to Anorexia Nervosa:

(show top 50) (show all 12437)
# Title Authors PMID Year
1
Haplotype analysis of the COMT-ARVCF gene region in Israeli anorexia nervosa family trios. 9 38 8
16118784 2005
2
Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. 9 38 8
15523490 2005
3
Combined family trio and case-control analysis of the COMT Val158Met polymorphism in European patients with anorexia nervosa. 9 38 8
14681918 2004
4
Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients. 9 38 8
11317231 2001
5
Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. 38 8
18855537 2008
6
Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates. 38 8
16152574 2005
7
Linkage analysis of anorexia nervosa incorporating behavioral covariates. 38 8
11912184 2002
8
Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. 38 8
11799475 2002
9
Anorexia nervosa and major depression: shared genetic and environmental risk factors. 38 8
10698830 2000
10
A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. 38 8
9672050 1998
11
Mortality in anorexia nervosa. 38 8
7793446 1995
12
Anorexia nervosa: a study of 34 twin pairs and one set of triplets. 38 8
6593110 1984
13
Significant linkage on chromosome 10p in families with bulimia nervosa. 8
12476400 2003
14
Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. 9 38
20339027 2010
15
Peptide YY levels across pubertal stages and associations with growth hormone. 9 38
20375207 2010
16
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 9 38
20195875 2010
17
Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. 9 38
19931436 2010
18
Possible involvement of ghrelin on pain threshold in obesity. 9 38
19883981 2010
19
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. 9 38
18574484 2010
20
Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. 9 38
19926712 2010
21
[Neuropeptide Y, ghrelin and leptin plasma levels in anorexia nervosa patients and their changes during six-week refeeding]. 9 38
19947235 2009
22
Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. 9 38
19659925 2009
23
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 9 38
19741568 2009
24
Leptin deficiency: clinical implications and opportunities for therapeutic interventions. 9 38
19730134 2009
25
Adipocyte fatty acid binding protein during refeeding of female patients with anorexia nervosa. 9 38
19421706 2009
26
Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa. 9 38
19568484 2009
27
Leptin concentration indexed to fat mass is increased in untreated anorexia nervosa (AN) patients. 9 38
18803679 2009
28
Brain-derived neurotrophic factor (BDNF) and set-shifting in currently ill and recovered anorexia nervosa (AN) patients. 9 38
18752728 2009
29
The role of leptin and cortisol in hyperactivity in patients with acute and weight-recovered anorexia nervosa. 9 38
19296912 2009
30
[Relationships of hormones of adipose tissue and ghrelin to bone metabolism]. 9 38
19662887 2009
31
Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. 9 38
19046818 2009
32
Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa. 9 38
18926548 2009
33
Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. 9 38
18995969 2009
34
Leptin in humans: lessons from translational research. 9 38
19176740 2009
35
Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders. 9 38
19176730 2009
36
NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. 9 38
20066808 2009
37
The role of ghrelin in the regulation of food intake in patients with obesity and anorexia nervosa. 9 38
18380540 2009
38
Hypercaloric diets differing in fat composition have similar effects on serum leptin and weight gain in female subjects with anorexia nervosa. 9 38
19185771 2009
39
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. 9 38
19093738 2009
40
Leptin and its associations with measures of psychopathology in patients with anorexia nervosa. 9 38
19018447 2009
41
Serum concentrations of adipocyte fatty acid binding protein in patients with anorexia nervosa. 9 38
18657008 2009
42
Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. 9 38
19755753 2009
43
Mecasermin (recombinant human insulin-like growth factor I). 9 38
19198769 2009
44
Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. 9 38
18474361 2008
45
Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18F]MPPF PET scan study. 9 38
18639866 2008
46
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 9 38
18728162 2008
47
The endocrinopathies of anorexia nervosa. 9 38
19095609 2008
48
Surged leptin/ghrelin secretion associated with anorexia nervosa. 9 38
18955869 2008
49
Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. 9 38
19014633 2008
50
Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. 9 38
17919459 2008

Variations for Anorexia Nervosa

Expression for Anorexia Nervosa

Search GEO for disease gene expression data for Anorexia Nervosa.

Pathways for Anorexia Nervosa

Pathways related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 PYY PRL POMC NPY LEPR LEP
2
Show member pathways
12.84 POMC HTR2A GHRH GH1 CRH BDNF
3
Show member pathways
12.29 PRL LEPR LEP GH1
4
Show member pathways
12.24 LEPR LEP IGF1 ADIPOQ
5
Show member pathways
12.17 PRL LEPR LEP GHR GH1
7
Show member pathways
11.98 POMC LEP IGF1 GHRL GH1
8 11.78 RETN LEP IGF1 GH1 ADIPOQ
9 11.54 IGF1 GHRH GH1 BDNF
10 11.5 IGF1 GHR GH1
11 11.33 PRL LEPR LEP
12
Show member pathways
11.22 PRL GHR GH1
13
Show member pathways
11.02 POMC LEPR LEP
14 10.94 POMC NPY LEPR LEP AGRP ADIPOQ
15 10.79 POMC AGRP
16 10.32 POMC CRH

GO Terms for Anorexia Nervosa

Cellular components related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 RETN PYY PRL POMC NPY LEPR
2 neuronal cell body GO:0043025 9.65 HTR2A GHR CRH CCK AGRP
3 extracellular space GO:0005615 9.53 RETN PYY PRL POMC NPY LEP
4 endosome lumen GO:0031904 9.32 PRL GH1
5 growth hormone receptor complex GO:0070195 9.16 GHR GH1

Biological processes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 PRL LEP IGF1 HTR2A GHRH CRH
2 response to drug GO:0042493 9.92 SLC6A4 HTR2A CRH ADIPOQ
3 glucose homeostasis GO:0042593 9.9 POMC LEPR LEP ADIPOQ
4 female pregnancy GO:0007565 9.89 PRL LEP CRH
5 response to insulin GO:0032868 9.87 RETN LEP AGRP
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 LEP IGF1 GH1
7 neuropeptide signaling pathway GO:0007218 9.87 PYY POMC NPY AGRP
8 regulation of blood pressure GO:0008217 9.85 POMC NPY LEP
9 glucose metabolic process GO:0006006 9.85 LEP GHRL ADIPOQ
10 response to hypoxia GO:0001666 9.83 SLC6A4 LEP ADIPOQ
11 hormone-mediated signaling pathway GO:0009755 9.83 GHRL GHR AGRP
12 positive regulation of cold-induced thermogenesis GO:0120162 9.83 LEPR LEP GHRL ADIPOQ
13 memory GO:0007613 9.8 SLC6A4 HTR2A CCK BDNF
14 feeding behavior GO:0007631 9.79 PYY NPY AGRP
15 response to ethanol GO:0045471 9.78 LEP CRH ADIPOQ
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 LEP IGF1 GHR GH1
17 regulation of multicellular organism growth GO:0040014 9.77 PRL IGF1 GHR
18 response to estradiol GO:0032355 9.75 SLC6A4 LEP GH1
19 negative regulation of gluconeogenesis GO:0045721 9.72 LEPR ADIPOQ
20 hormone metabolic process GO:0042445 9.72 LEP GHR
21 energy reserve metabolic process GO:0006112 9.72 LEPR LEP
22 insulin-like growth factor receptor signaling pathway GO:0048009 9.71 IGF1 GHR
23 central nervous system neuron development GO:0021954 9.71 NPY LEP
24 regulation of feeding behavior GO:0060259 9.71 LEPR AGRP
25 positive regulation of growth GO:0045927 9.71 GHRL GH1
26 eating behavior GO:0042755 9.71 LEP CCK AGRP
27 growth hormone receptor signaling pathway GO:0060396 9.7 GHR GH1
28 sexual reproduction GO:0019953 9.7 LEPR LEP
29 positive regulation of growth hormone secretion GO:0060124 9.69 GHRL GHRH
30 response to nutrient GO:0007584 9.69 SLC6A4 LEP ADIPOQ
31 negative regulation of appetite GO:0032099 9.68 LEP CCK
32 leptin-mediated signaling pathway GO:0033210 9.68 LEPR LEP
33 positive regulation of feeding behavior GO:2000253 9.67 GHRL AGRP
34 growth hormone secretion GO:0030252 9.67 GHRL GHRH
35 regulation of bone remodeling GO:0046850 9.67 LEPR LEP
36 positive regulation of multicellular organism growth GO:0040018 9.67 GHRL GHRH GHR GH1
37 positive regulation of behavioral fear response GO:2000987 9.66 CRH CCK
38 positive regulation of cortisol secretion GO:0051464 9.65 GHRL CRH
39 positive regulation of corticotropin secretion GO:0051461 9.65 GHRL CRH
40 negative regulation of glucagon secretion GO:0070093 9.64 LEP CRH
41 bone mineralization involved in bone maturation GO:0035630 9.63 LEP IGF1
42 positive regulation of appetite GO:0032100 9.63 NPY GHRL
43 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.63 IGF1 GHRH GH1
44 circadian rhythm GO:0007623 9.62 SLC6A4 LEP AGRP ADIPOQ
45 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 PRL GHR GH1
46 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.56 GHRL CRH
47 positive regulation of JAK-STAT cascade GO:0046427 9.56 PRL LEP GHR GH1
48 bone growth GO:0098868 9.55 LEPR LEP
49 response to nutrient levels GO:0031667 9.55 PRL LEP GHRL GH1 ADIPOQ
50 response to leptin GO:0044321 9.4 LEPR

Molecular functions related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.8 POMC NPY LEP CRH AGRP ADIPOQ
2 G protein-coupled receptor binding GO:0001664 9.56 PYY POMC NPY GHRL
3 serotonin binding GO:0051378 9.43 SLC6A4 HTR2A
4 neuropeptide hormone activity GO:0005184 9.43 PYY NPY GHRH CRH CCK AGRP
5 prolactin receptor binding GO:0005148 9.4 PRL GH1
6 hormone activity GO:0005179 9.4 RETN PYY PRL POMC NPY LEP
7 growth hormone-releasing hormone activity GO:0016608 9.37 GHRL GHRH
8 peptide hormone receptor binding GO:0051428 9.33 LEP GHRH CCK

Sources for Anorexia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....